NURR1 involvement in recombinant tissue-type plasminogen activator treatment complications after ischemic stroke

Stroke

Volumn 46, Issue 2, 2015, Pages 477-484

  Merino Zamorano, Cristina ^a   Hernández Guillamon, Mar ^a   Jullienne, Amandine ^b   Le Béhot, Audrey ^b   Bardou, Isabelle ^b   Parés, Mireia ^a   Fernández Cadenas, Israel ^a   Giralt, Dolors ^a   Carrera, Caty ^a   Ribó, Marc ^c   Vivien, Denis ^b   Ali, Carine ^b   Rosell, Anna ^a   Montaner, Joan ^a,c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITÉ DE CAEN   (France)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

hemorrhagic transformation; NURR1; stroke; tissue type plasminogen activator

Indexed keywords

ALTEPLASE; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 2; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; NUCLEAR FACTOR KAPPA BETA 2; NUCLEAR RECEPTOR RELATED FACTOR 1; OXYGEN; SMAD3 PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; NR4A2 PROTEIN, HUMAN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CELL; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOEMBOLISM; ANIMAL; BIOSYNTHESIS; BLOOD; CELL LINE; CHEMICALLY INDUCED; INFLAMMATION; MIDDLE AGED; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CELL LINE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; MALE; MICE; MIDDLE AGED; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84922271820     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006826     Document Type: Article

References (22)

1. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893-903. doi: 10.1056/NEJMoa1214300.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
3. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774. doi: 10.1016/S0140-6736(04)15692-4.
4. Abu Fanne R, Nassar T, Yarovoi S, Rayan A, Lamensdorf I, Karakoveski M, et al. Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology. 2010;58:972-980. doi: 10.1016/j. neuropharm.2009.12.017.
5. Mages HW, Rilke O, Bravo R, Senger G, Kroczek RA. NOT, a human immediate-early response gene closely related to the steroid/thyroid hormone receptor NAK1/TR3. Mol Endocrinol. 1994;8:1583-1591. doi: 10.1210/mend.8.11.7877627.
6. Law SW, Conneely OM, DeMayo FJ, O'Malley BW. Identification of a new brain-specific transcription factor, NURR1. Mol Endocrinol. 1992;6:2129-2135. doi: 10.1210/mend.6.12.1491694.
7. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2009;137:47-59. doi: 10.1016/j.cell.2009.01.038.
8. Zetterström RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 1997;276: 248-250.
9. Aherne CM, McMorrow J, Kane D, FitzGerald O, Mix KS, Murphy EP. Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. Mol Immunol. 2009;46:3345-3357. doi: 10.1016/j.molimm.2009.07.019.
10. Sakurada K, Ohshima-Sakurada M, Palmer TD, Gage FH. Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development. 1999;126:4017-4026.
11. Honkaniemi J, Sharp FR. Global ischemia induces immediate-early genes encoding zinc finger transcription factors. J Cereb Blood Flow Metab. 1996;16:557-565. doi: 10.1097/00004647-199607000-00005.
12. Honkaniemi J, States BA, Weinstein PR, Espinoza J, Sharp FR. Expression of zinc finger immediate early genes in rat brain after permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1997;17:636-646. doi: 10.1097/00004647-199706000-00005.
13. Erdö F, Trapp T, Mies G, Hossmann KA. Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in mice. Acta Neuropathol. 2004;107:127-136. doi: 10.1007/s00401-003-0789-8.
14. Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19:1872-1874. doi: 10.1096/fj.04-3458fje.
15. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke. 2007;38:2771-2778. doi: 10.1161/STROKEAHA.107.487520.
16. Macrez R, Obiang P, Gauberti M, Roussel B, Baron A, Parcq J, et al. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke. 2011;42:2315-2322. doi: 10.1161/STROKEAHA.110.606293.
17. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
18. Ishrat T, Soliman S, Guan W, Saler M, Fagan SC. Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des. 2012;18:3677-3684.
19. Bensinger SJ, Tontonoz P. A Nurr1 pathway for neuroprotection. Cell. 2009;137:26-28. doi: 10.1016/j.cell.2009.03.024.
20. O'Kane M, Markham T, McEvoy AN, Fearon U, Veale DJ, FitzGerald O, et al. Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-alpha inhibition. J Invest Dermatol. 2008;128:300-310. doi: 10.1038/sj.jid.5701023.
21. Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S, Yamamura T. Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc Natl Acad Sci U S A. 2008;105:8381-8386. doi: 10.1073/pnas.0803454105.
22. Johnson MM, Michelhaugh SK, Bouhamdan M, Schmidt CJ, Bannon MJ. The transcription factor NURR1 exerts concentration-dependent effects on target genes mediating distinct biological processes. Front Neurosci. 2011;5:135. doi: 10.3389/fnins.2011.00135.